Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global onychomycosis market size was exhibited at USD 3.49 billion in 2022 and is projected to hit around USD 5.46 billion by 2032, growing at a CAGR of 4.57% during the forecast period 2023 to 2032.

onychomycosis market size

Key Pointers:

  • North America held the largest share of 41.54% of the market in 2022
  • Distal subungual onychomycosis (DSO) segment held the largest share of 42.19% of the market in 2022.
  • Topical segment held the largest share of 31.69% of the market in 2022. 
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position

Onychomycosis Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 3.65 Billion

Market Size by 2032

USD 5.46 Billion

Growth Rate from 2023 to 2032

CAGR of 4.57%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Type, Treatment

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Bausch Health Companies Inc.; GSK plc; Abbott; Pfizer Inc.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Cipla Inc.; Merck & Co., Inc.; Novartis AG; Sun Pharmaceutical Industries Ltd.

 

The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Some of the prominent players in the Onychomycosis Market include:

  • Bausch Health Companies Inc.
  • GSK plc
  • Abbott
  • Pfizer Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Onychomycosis market.

By Type 

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Other Types

By Treatment 

  • Oral
  • Topical
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global onychomycosis market size was exhibited at USD 3.49 billion in 2022 and is projected to hit around USD 5.46 billion by 2032

The global onychomycosis market is expected to grow at a compound annual growth rate of 4.57% from 2023 to 2032

North America dominated the onychomycosis market with a share of 41.54% in 2022. This is attributable to better access to healthcare, presence of a wide target population, and high adoption of treatment.

Some key players operating in the onychomycosis market include Bausch Health Companies Inc., GSK plc, Abbott, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, and Sun Pharmaceutical Industries Ltd.

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers